AKT1 and renal cell carcinoma: Very similar results were also observed in the primary human RCC cells, where WYE-687 (100 nM, 2 hours) treatment blocked mTORC1 (p-S6K1, p-S6) and mTORC2 (p-Akt Ser 473)activation simantanuously (Fig 4B).